Clinical trials: Hypertrophic Cardiomyopathies
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
This is an early study of a catheter-based minimally invasive procedure called SESAME to slice thick heart muscle as described below.
- Conditions
- Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction, Systolic Anterior Motion
- Trial name
- NCT07806149
- Testing
- SESAME Procedure
- Where
- 8 sites in United States
- Volunteers
- 200 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cardiovascular Diseases, Heart Diseases
Genetic Analysis of Familial Hypertrophic Cardiomyopathy
To map the genetic defect responsible for familial hypertrophic cardiomyopathy.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Myocardial Diseases, Cardiomyopathy, Hypertrophic
- Trial name
- NCT00005251
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cardiomyopathies, Hypertrophic Cardiomyopathy
The SMARTER Cardiomyopathy Study
Cardiomyopathies are diseases of the heart muscle. Known genetic factors may account for some cardiomyopathy cases but there is still much to understand about the genetic and environmental causes and how the disease progresses.
- Conditions
- Cardiomyopathies, Hypertrophic Cardiomyopathy, Dilated Cardiomyopathy
- Trial name
- SMARTER-CM (NCT05750147)
- Testing
- Blood Sample Collection
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Imperial College London
Heart Failure With Preserved Ejection Fraction, Hypertrophic Cardiomyopathy
Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition
Heart scarring, also known as fibrosis, plays a major role in a lot of heart muscle abnormalities. These abnormalities of the heart muscle can lead to major issues such as symptoms of heart failure, dangerous heart rhythm…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Hypertrophic Cardiomyopathy, Cardiac Sarcoidosis, Hypertensive Heart Disease
- Trial name
- CHIEFTain (NCT06409585)
- Testing
- 68Ga-FAPI or 18F-AlF-FAPI cardiac PET-MR, Echocardiogram, Cardiac MRI
- Where
- United Kingdom
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Hypertrophic Cardiomyopathy
Exercise Training in Hypertrophic Cardiomyopathy: (SAFE-HCM)
To explore the feasibility, safety, health and psychological benefits of a 12-week high intensity exercise programme in a young group of individuals with hypertrophic cardiomyopathy (HCM).
- Trial name
- SAFE-HCM (NCT05459467)
- Testing
- Exercise
- Where
- 3 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- St George's, University of London
Hypertrophic Cardiomyopathy
Evaluating Microvascular Dysfunction in Symptomatic Patients With HypertroPhic CaRdiomyopathy
Patients with hypertrophic cardiomyopathy are being compared to a control group. IMR will be assessed with a pressure wire. Clinical f/u at 3 months and 6 months and a 48 hour holter monitor.
- Trial name
- PRIMARy (NCT02994615)
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Non-obstructive Hypertrophic Cardiomyopathy
A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial
The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.
- Trial name
- IMPROVE-HCM (NCT04826185)
- Testing
- IMB-1018972
- Where
- 14 sites in United States, United Kingdom
- Volunteers
- 67 people
- Sponsor
- Imbria Pharmaceuticals, Inc.
Hypertrophic Cardiomyopathy, Hearing Loss
Refining Information Technology Support for Genetics in Medicine
The clinical use of genetic testing is expanding and, as a result, the number of variants identified in patients is growing. Knowledge of the clinical impact of these variants improves over time.
- Conditions
- Hypertrophic Cardiomyopathy, Hearing Loss, Cancer
- Trial name
- RISGIM (NCT01225978)
- Testing
- GeneInsight Clinic (GIC)
- Where
- 9 sites in United States, Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Myocardial Reperfusion Injury, Cardiac Output, Low
Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy
Open-heart surgery causes injury of the heart muscle. Although this is usually mild, temporary and reversible, if it is severe it can endanger life and require additional high cost care.
- Conditions
- Myocardial Reperfusion Injury, Cardiac Output, Low, Hypertrophy, Left Ventricular
- Trial name
- HYPER (NCT00989508)
- Testing
- Perhexiline
- Where
- United Kingdom
- Volunteers
- 220 people
- Sponsor
- University Hospital Birmingham
Hypertrophic Cardiomyopathy, Sudden Cardiac Death
PRecIsion Medicine in CardiomyopathY
This is a retrospective cohort study of pediatric hypertrophic cardiomyopathy (HCM) patients using chart and registry review methodology.
- Trial name
- PRIMaCY (NCT04036799)
- Volunteers
- 572 people
- Sponsor
- The Hospital for Sick Children
Hypertrophic Cardiomyopathy, Obstructive
REFINE-HCM: Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy
This is a prospective, multicenter, randomized, parallel-controlled, superiority clinical trial designed to evaluate the efficacy and safety of a transcatheter intramyocardial septal radiofrequency ablation system for the…
- Trial name
- REFINE-HCM (NCT07006493)
- Testing
- Transcatheter Intramyocardial Septal Radiofrequency Ablation System
- Where
- 2 sites in China
- Volunteers
- 124 people
- Sponsor
- SuZhou Sinus Medical Technologies Co.,Ltd
Hypertrophic Cardiomyopathy
Genetic Predictors of Outcome in HCM Patients
This is a retrospective review of the data available on patients and their family members with HCM and prospective follow-up of this cohort for clinical outcome and diagnostic studies.
- Trial name
- NCT00156429
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- University of Pittsburgh
Hypertrophic Cardiomyopathy
Surgical Septal Myectomy vs Percutaneous Transluminal Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy
The aim of this randomized trial is to compare the improvement in exercise capacity among patients with highly symptomatic hypertrophic obstructive cardiomyopathy despite optimal medical treatment who undergo alcohol septal…
- Trial name
- AMARONE (NCT04684290)
- Testing
- Alcohol Septal Ablation, Surgical Septal Myectomy
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- St. Antonius Hospital
Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy Federated Learning Implementation Platform
HCM FLIP study is a two-phase protocol focusing on the detection of Hypertrophic Cardiomyopathy using Electrocardiograms and Echocardiograms through Federated Learning.
- Trial name
- HCM FLIP (NCT06461468)
- Where
- 6 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- American Heart Association
Left Ventricular Hypertrophy
Belgian Screening Project for the Detection of Anderson-Fabry Disease in Hypertrophic Cardiomyopathy
The purpose of this study is to determine the prevalence of Fabry mutations in patients with left ventricular hypertrophy (moderate to severe), as measured by echocardiography.This study is a screening study
- Trial name
- NCT01198899
- Testing
- blood sampling
- Where
- 9 sites in Belgium
- Volunteers
- 540 people
- Sponsor
- University Hospital, Ghent
Hypertrophic Obstructive Cardiomyopathy
Mobilization of Endothelial Progenitor Cells and Aspirin
Aspirin at doses used during acute myocardial infarction may inhibit the mobilization of endothelial progenitor cells (EPCs).
- Trial name
- TROPHIC 3 (NCT02674958)
- Testing
- Aspirin
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Hypertrophic Obstructive Cardiomyopathy
Edge-to-edge Mitral Valve Repair in the Surgical Treatment for Hypertrophic Cardiomyopathy
Objective of the study: to evaluate whether edge-to-edge technique improves clinical and hemodynamic results in patients scheduled to septal myectomy for severely symptomatic hypertrophic obstructive cardiomyopathy.
- Trial name
- PRIZMA-pilot (NCT04470102)
- Testing
- mitral valve repair by edge-to-edge technique, Septal myectomy
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Cardiomyopathy, Hypertrophic, Familial
Signs and Symptoms of Genetic Abnormalities Linked to Inherited Heart Disease
Genetically inherited heart diseases (familial cardiomyopathies) are conditions affecting the heart passed on to family members through abnormalities in genetic information.
- Trial name
- NCT00001881
- Where
- United States
- Volunteers
- 9,999 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypertrophic Cardiomyopathy (HCM)
A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population
This study is a prospective cohort study aimed at exploring the baseline characteristics and treatment patterns of the Chinese population with hypertrophic cardiomyopathy (HCM) in real-world settings.
- Trial name
- HCM (NCT06775665)
- Testing
- No interventions were applied to the patients.
- Where
- 2 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Cardiomyopathy
Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)
The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in adults diagnosed with symptomatic obstructive hypertrophic cardiomyopathy (HOCM) receiving cibenzoline in Japan
- Trial name
- NCT07541833
- Testing
- Mavacamten
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Bristol-Myers Squibb